Immune checkpoint blockade (ICB) therapy targeting the PD-L1 (e.g., atezolizumab, avelumab, and durvalumab)/PD-1 (e.g., nivolumab, pembrolizumab, spartalizumab, and cemiplimab) axis reactivates T-cell immunity in tumor microenvironment [12]. The gene discussed is CD274; the disease is neoplasm.